PD-1 Agonist Therapy for Post-Stroke Cerebral Edema
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stroke, particularly large vessel occlusions, focus on restoring cerebral blood flow but lack effective methods to reduce cerebral edema and neuroinflammation, leading to significant disability and mortality.
Innovation Solution
Administering a therapeutically effective amount of a PD-1 agonist systemically to activate PD-1 on peripheral monocytes, which infiltrate the brain, shifting their phenotype to a non-inflammatory subtype and reducing their numbers, thereby limiting secondary inflammatory injury and cerebral edema.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current stroke treatments focus on restoring cerebral blood flow using intravenous thrombolytics or mechanical thrombectomy, then ischemic cell death is minimized, but cerebral edema and neuroinflammation are not effectively reduced
Solution Approach 1:
The patent converts the harmful inflammatory response into a beneficial therapeutic effect by administering PD-1 agonists that modulate monocyte phenotype. The treatment transforms the natural post-stroke inflammatory cascade from a harmful process causing edema and secondary injury into a controlled response that limits damage while maintaining necessary immune surveillance and tissue repair functions.
Solution Approach 2:
The patent changes the phenotypic parameters of monocytes by activating PD-1 receptors, shifting them from a pro-inflammatory state to a less inflammatory or anti-inflammatory state. This parameter change in monocyte activation status directly reduces cerebral edema and neuroinflammation while preserving the therapeutic benefits of blood flow restoration.
2Reliability
If supportive care is provided after stroke, then patient survival is maintained, but disability and mortality rates remain high due to lack of effective edema reduction
Solution Approach 1:
The patent applies preliminary action by administering PD-1 agonists in the acute phase following stroke to prevent the development of severe cerebral edema and neuroinflammation. This proactive intervention occurs before the full inflammatory cascade progresses to cause irreversible damage, thereby reducing disability and mortality while maintaining patient survival.
3Reliability
If monocytes infiltrate the brain after stroke, then immune response is activated, but secondary inflammatory injury and cerebral edema increase
Solution Approach 1:
The patent applies local quality by selectively modulating the phenotype of infiltrating monocytes within the brain parenchyma while preserving their immune functions. The PD-1 agonist treatment creates a localized phenotypic shift in monocytes at the site of injury, reducing their inflammatory harmful effects while maintaining their ability to participate in tissue repair and immune surveillance.
Data Source
AI summary
Disclosed herein are methods of reducing or preventing cerebral edema in a subject after a stroke by administering systemically a therapeutically effective amount of a PD-1 agonist to the subject. Also disclosed herein are methods of treating neuroinflammation, improving gait, improving sensorimotor deficits, reducing the number of PD-1 positive monocytes in the brain, decreasing intracranial pressure, shifting the phenotype of monocytes in the brain from a classical inflammatory subtype to a non-classical subtype, and limiting or reducing secondary inflammatory injury, reducing a risk of a second or more stroke events in a subject after a stroke.